A new tooth-regrowing drug has finally entered human trials after months of waiting and promising clinical trials on mice and ...
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...
Psychedelic industry faced setbacks, cannabis was almost rescheduled and overdose deaths dropped — but not for all ...
A once-groundbreaking sickle cell disease drug — at the center of a $5.4 billion acquisition two years ago — is the subject ...
People with missing teeth may be able to grow new ones, say Japanese dentists testing a pioneering drug they hope will offer ...
About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.
Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration ...
Medicare drug price negotiation could have significant impacts on investment in post-approval studies for cancer treatment ...
Prothena's stock soared 34% despite setbacks, with promising partnerships and potential in Parkinson's and Alzheimer's ...
T he US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to a cancer drug called dostarlimab ...
Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback